Arsanis Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Arsanis Inc
TickerXFOR
CIK #0001501697
CUSIP98420X103
SectorLife Sciences - Biological Products, (No Disgnostic Substances)
Address890 Winter Street, Suite 230, Waltham, MA 02451
Source [EDGAR]
CIK Filing 2011 - 2024
[0001501697] 10-K
[0001501697] 10-Q
[0001501697] 3
[0001501697] 4
[0001501697] 8-K
[0001501697] D
[0001501697] SC 13D
[0001501697] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Empery Asset Management LP X4 Pharmaceuticals Inc [2023-01-13] 5.12
Growth Equity Opportunities 18 VGE LLC X4 Pharmaceuticals Inc [2022-07-19] 0.9
Lincoln Park Capital Fund LLC X4 Pharmaceuticals Inc [2022-01-19] 6.44
Point72 Asset Management LP X4 Pharmaceuticals Inc [2021-11-17] 5.6
Hirschman Orin X4 Pharmaceuticals Inc [2021-06-29] 6.2
BlackRock Inc X4 Pharmaceuticals Inc [2021-02-02] 6.3
Ikarian Capital LLC X4 Pharmaceuticals Inc [2020-12-30] 5.1
RA Capital Management LP X4 Pharmaceuticals Inc [2020-02-14] 0.9
EcoR1 Capital LLC X4 Pharmaceuticals Inc [2019-12-17] 7.2
Bain Capital Life Sciences Fund LP X4 Pharmaceuticals Inc [2019-12-09] 9.99
FMR LLC X4 Pharmaceuticals Inc [2019-05-10] 0.0
Biotechnology Value Fund L P X4 Pharmaceuticals Inc [2019-04-23] 6.4
Cormorant Asset Management LP X4 Pharmaceuticals Inc [2019-04-22] 5.93
OrbiMed Advisors LLC X4 Pharmaceuticals Inc [2019-04-19] 0.8
Flynn James E X4 Pharmaceuticals Inc [2019-04-16] 6.69
Ragan Paula X4 Pharmaceuticals Inc [2019-03-22] 11.0
Bill & Melinda Gates Foundation X4 Pharmaceuticals Inc [2019-03-15] 1.8
X4 Pharmaceuticals Inc Arsanis Inc [2018-12-06] 48.2
SVLSF V LLC Arsanis Inc [2018-02-14] 6.5
Bill & Melinda Gates Foundation Arsanis Inc [2018-02-13] 5.1
FMR LLC Arsanis Inc [2017-12-11] 0.0
OrbiMed Advisors LLC Arsanis Inc [2017-11-30] 13.07
Polaris Venture Partners V LP Arsanis Inc [2017-11-29] 13.2
New Enterprise Associates 16 LP Arsanis Inc [2017-11-29] 14.6
Form 3/4/5 Filer 2011 - 2024
McGirr David W J
X4 Pharmaceuticals, Inc
Aliski William
Bridger Gary
Lawton Alison Frances
Wyzga Michael S
de Craecker Francoise
Ragan Paula
Taveras Arthur
DiBiase Mary
Mostafa Adam S.
Baldry Mark
Meisner Derek M
Stewart Murray
Cadavid Diego
Russo Rene
Skerlj Renato
Kelley Lynne E
Blech Isaac
Gray Michael
Chang Carmen
Behbahani Ali
Gerngross Tillman U.
Clark William D
Nessi Claudio
Ross Michael Jay
Schulman Amy W
McGuire Terrance
Gordon Carl L
Stevens Anthony Chris
Nagy Eszter
Mantus David
Puttagunta Chetan
Sandell Scott D
Sonsini Peter W.
Viswanathan Ravi
Alexandria Venture Investments, LLC
Bill & Melinda Gates Foundation
Herr Stefan
EMBL Technology Fund II GmbH & Co. KG
Muhlenbeck Frank
EMBL Ventures Verwaltungs GmbH
Adams Jan
NeoMed Innovation V Ltd
NeoMed Innovation V L.P.
NeoMed Management (Jersey) Ltd
GV 2016 GP LLC
Alphabet Inc.
GV 2016 LP
GV 2016 GP LP
Anna-Maria & Stephen Kellen Foundation, Inc.
Section 32 GP 1, LLC
Section 32 Fund 1, LP
Maris William J
SVLSF V LLC
SV Life Sciences Fund VI, L.P.
SV Life Sciences Fund V LP
SV Life Sciences Fund V Strategic Partners, L.P.
SV Life Sciences Fund VI Strategic Partners, L.P.
Isaly Samuel D
OrbiMed Advisors LLC
OrbiMed Capital GP IV LLC
Polaris Venture Partners Special Founders' Fund V, L.P.
Flint Jonathan A
Polaris Venture Partners V, L.P.
Polaris Venture Partners Founders' Fund V, L.P.
Polaris Venture Management Co. V, L.L.C.
Polaris Venture Partners Entrepreneurs' Fund V, L.P.
New Enterprise Associates 16, L.P.
NEA Partners 16, L.P.
NEA 16 GP LLC
Barris Peter J
Baskett Forest
Florence Anthony A. Jr.
Makhzoumi Mohamad
Mott David M
Sakoda Jon
SVLSF VI LLC
Form 13F Holdings
Firm Period DFND Voting Shares
Bain Capital Life Sciences Investors, LLC [2023-03-31] SOLE 12,202,510.0 12,202,510.0
NEA Management Company LLC [2023-03-31] DFND 11,736,793.0 11,736,793.0
OrbiMed Advisors LLC [2023-03-31] SOLE 5,817,726.0 5,817,726.0
Perceptive Advisors LLC [2023-03-31] SOLE 4,545,454.0 4,545,454.0
AXA Sa [2023-03-31] DFND 4,396,468.0 4,396,468.0
Vanguard Group Inc [2023-03-31] SOLE 0.0 4,317,008.0
TRI Locum Partners LP [2023-03-31] SOLE 3,878,484.0 3,878,484.0
Parkman Healthcare Partners LLC [2023-03-31] SOLE 2,797,147.0 2,797,147.0
Cormorant Asset Management LP [2023-03-31] DFND 1,628,980.0 1,628,980.0
Geode Capital Management LLC [2023-03-31] DFND 1,108,684.0 1,108,684.0
Millennium Management LLC [2023-03-31] SOLE 1,080,213.0 1,080,213.0
Schonfeld Strategic Advisors LLC [2023-03-31] SOLE 1,037,000.0 1,037,000.0
Lynwood Capital Management Inc. [2023-03-31] SOLE 900,000.0 900,000.0
Ghost Tree Capital LLC [2023-03-31] SOLE 850,000.0 850,000.0
Point72 Asset Management LP [2023-03-31] DFND 0.0 650,000.0
JPMorgan Chase & Co [2023-03-31] DFND 626,047.0 626,047.0
Scoggin Management LP [2023-03-31] DFND 484,796.0 484,796.0
Simplify Asset Management Inc [2023-03-31] SOLE 400,000.0 400,000.0
Ikarian Capital LLC [2023-03-31] SOLE 349,133.0 349,133.0
BlackRock Inc. [2023-03-31] SOLE 343,580.0 343,580.0
New Leaf Venture Partners LLC [2023-03-31] DFND 335,000.0 335,000.0
Susquehanna International Group LLP [2023-03-31] DFND 282,547.0 332,847.0
Northern Trust Corp [2023-03-31] DFND 67.0 224,470.0
Bank of New York Mellon Corp [2023-03-31] DFND 171,193.0 171,193.0
State Street Corp [2023-03-31] DFND 170,633.0 170,633.0
Citadel Advisors LLC [2023-03-31] DFND 160,961.0 160,961.0
Virtu Financial LLC [2023-03-31] DFND 113,489.0 113,489.0
UBS Group AG [2023-03-31] DFND 0.0 100,000.0
XTX Topco Ltd [2023-03-31] DFND 96,649.0 96,649.0
Stifel Financial Corp [2023-03-31] DFND 93,497.0 93,497.0
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com